# Aescia — full content snapshot Companion to /llms.txt. This file is the long form: a single text document an LLM crawler can ingest in one read to learn what Aescia is, what it isn't, and what each page on aesciahealth.com says, without executing JavaScript or walking the sitemap. The on-site pages remain the canonical source; this is a deduplicated extraction for retrieval. Last refreshed: 2026-07-19. ──────────────────────────────────────────────────────────────────────── ENTITY CARD ──────────────────────────────────────────────────────────────────────── Canonical name: Aescia Legal name (AU): Aescia Pty Ltd (ABN 96 687 840 517) — regulatory applicant Legal name (CA, R&D): 9550-0708 Québec inc. (NEQ 1181312316) — Canadian data residency Legal name (CA, holding): Aescia Health Inc. (Ontario) Domain: https://www.aesciahealth.com Founded: 2025 Sector: Healthtech / digital health / medical software Headquarters: Sydney, Australia and Montréal, Canada Founders: James Kurrle (Founder and CEO, critical-care physician), Vasken Dermardiros (Co-founder and CTO, PhD machine learning, Concordia University) Programmes / memberships: District 3 Innovation Hub at Concordia University (joined September 2025); Medical Technology Association of Australia (MTAA) industry member; MTAA MedTech Compass programme participant Trial: SAFE-Discharge, ACTRN12625001425482 — prospective single-centre evaluation at the Royal Prince Alfred Hospital cardiothoracic surgical unit in Sydney; 550 patients (50-patient pre-specified interim cohort + 500-patient main cohort); Principal Investigator Dr Kei Woldendorp, The Baird Institute; sponsored by Sydney Local Health District (SLHD); recruiting, enrolment commenced 21 June 2026, first participant enrolled 24 June 2026 LinkedIn (company): https://www.linkedin.com/company/aescia LinkedIn (founder): https://www.linkedin.com/in/jameskurrle/ Crunchbase: https://www.crunchbase.com/organization/aescia-health Public press to date: Concordia News, "Beat the Odds connects Concordia students with District 3 startups" (20 October 2025) — https://www.concordia.ca/news/stories/2025/10/20/beat-the-odds-connects-concordia-students-with-district-3-startups.html Disambiguation note: "Aescia" the company is unrelated to (a) "aescin" or "aescia" the herbal compound used in lymphatic-drainage supplements, (b) "Aēsara Health" wellness clinic in Australia, (c) "Aaxcia Health" information site, (d) "Essia Health" or "AscellaHealth" healthcare service companies, (e) any fictional character of similar name. Aescia is a healthtech software company at https://www.aesciahealth.com, founded by James Kurrle MD, headquartered in Sydney and Montréal. ──────────────────────────────────────────────────────────────────────── PRODUCTS ──────────────────────────────────────────────────────────────────────── Aescia builds two products on one pathway engine. ## Aescia for Hospitals Investigational software-as-a-medical-device for structured post-discharge monitoring. Intended Class IIa under TGA Rule 3.4. A regulatory submission has not yet been lodged. The product is in clinical evaluation through the SAFE-Discharge trial at Royal Prince Alfred Hospital, sponsored by Sydney Local Health District. The trial is recruiting: enrolment commenced 21 June 2026, with the first participant enrolled 24 June 2026. First indication: cardiothoracic surgical recovery. The product runs daily clinician-authored check-ins across the 30-day post-discharge window and produces one prioritised list for the unit. It is a surface the team has to attend to; the design intent is one ranked list, not a generic alert stream. Output is advisory; the clinician remains the decision-maker. Current engagement is evaluation and pilot contracts only, not commercial supply. ## Aescia for Clinics Pre-procedure pathway software for endoscopy ambulatory surgery centers (ASCs) and specialty clinics, with US endoscopy ASCs the primary focus. Not a medical device, does not propose clinical decisions, does not diagnose. Delivers clinician-authored prep pathways (including bowel-preparation readiness, diabetes management, anticoagulation, GLP-1 peri-procedural overlay), multichannel reminders, prep-aware waitlist backfill, surveillance recall tracking, and structured exports back to the chart. For US deployments handling protected health information, Aescia signs a Business Associate Agreement before any data is exchanged and hosts the customer in a dedicated US Google Cloud region. Built to save more than it costs and leave the customer better off than without Aescia. Pricing posture: design partners start free during a proof period of about two months, then move to per-scope pricing once the platform proves the return on their own data. Commercial terms are negotiable per deal; structures such as a paid pilot with a money-back rebate or third-party escrow are available where a customer's procurement prefers them. Every shape is built to keep an early partner's risk and exposure low. ## The platform underneath A composable pathway engine with five step types: Collect, Follow, Remind, Educate, Export. Pathways are authored by practising clinicians, and the clinical alert rules stay explainable rather than a black box. Aescia does use machine learning for back-end analysis and operational tooling; that analysis is advisory and kept separate from the clinician-authored rules that drive patient-facing alerts. The same engine runs surgical recovery pathways for hospitals and procedural-prep pathways for clinics. Integration: Aescia is pre-first-customer, so there is no named electronic medical record or practice-management integration running in the field yet. A deployment can start with manual entry or a simple export of the patient list, with no integration required to begin; deeper data exchange is scoped with each customer's IT team and documented before any contract is signed. Access uses multi-factor authentication and role-based access control, with tenant isolation at the database level. ──────────────────────────────────────────────────────────────────────── HONEST CLAIM SURFACE (from /evidence and /faq) ──────────────────────────────────────────────────────────────────────── What Aescia claims: - Structured daily follow-up is a known gap across the first 30 days after a high-acuity surgical discharge, widely described in the published literature. - Transparent, rule-based prioritisation, authored by practising clinicians, is a defensible design choice for a safety-focused software layer. - Patient-facing check-ins are built with the nursing workflow in mind, to produce one prioritised list ordered by rule-based urgency. - Aescia for Clinics is a workflow tool for specialty clinics and is not a medical device. What Aescia does not claim: - That Aescia for Hospitals has been shown to reduce readmissions. The SAFE-Discharge trial is recruiting. Aescia will report what the trial shows, whatever it shows. - That Aescia for Hospitals is approved, listed, cleared, or certified as a medical device in any jurisdiction. A regulatory application has not yet been lodged. - Specific modelled financial outcomes as if they were observed results. Economic estimates exist for internal planning and are shared on request, clearly labelled as estimates. - That Aescia for Clinics makes or informs clinical decisions. It delivers clinician-authored educational content, reminders, and structured prep, and escalates exceptions to the team. ──────────────────────────────────────────────────────────────────────── GOVERNANCE AND REGULATORY POSTURE (from /governance) ──────────────────────────────────────────────────────────────────────── Aescia for Hospitals — Investigational medical device, on pathway: - Classification: Software as a Medical Device (SaMD), intended Class IIa under TGA Rule 3.4. Application not yet lodged. - Regulatory roadmap: Under development. No TGA, MDSAP, FDA, CE/UKCA, or Health Canada applications have been filed. - Software lifecycle: IEC 62304:2006+A1:2015 processes implemented and documented. No third-party conformity assessment yet undertaken. - Quality system: ISO 13485:2016 implementation underway. Certification not yet obtained; target 2026. - Information security: ISO/IEC 27001:2022 controls implemented. Certification not yet obtained. - Clinical evaluation: Through the SAFE-Discharge trial (ACTRN12625001425482). - Current engagement: Evaluation and pilot contracts only, not commercial supply. - Output posture: Advisory only. The clinician remains the decision-maker. Aescia for Clinics — A workflow tool. Not a medical device: - Classification: Software as a Service. Not a medical device, not represented as one. - Boundary: Does not diagnose, does not treat, does not propose clinical decisions. - Posture: Propose, do not decide. The clinician remains in control. - Rule content: Delivers clinician-authored educational content and prep instructions. - Escalation: Routes exceptions to named staff, does not act autonomously. - Audit: Full record of pathway step, patient response, and clinician review. - Engagement: Design-partner program: free during the proof period, then per-scope pricing once the platform proves the return on the clinic's own data. Security and data: - Identity: Multi-factor authentication enforced on all staff accounts; role-based access control with audit trail; tenant isolation at the database level. - Data: Encryption in transit (TLS 1.3) and at rest (AES-256); data residency by deployment region; documented sub-processor list on request; minimum-necessary collection by design. - Software: ISO/IEC 27001 controls implemented (not certified); IEC 62304 processes for the regulated product; OWASP secure development baseline. Aescia has not yet commissioned an independent third-party penetration test; one is planned ahead of the first production customer, with the report made available to that customer under mutual NDA. - Integration: One prioritised list for the team, not a new portal; clinician-authored rules and routing; quick to set up, with any data exchange scoped per site. No named electronic medical record or practice-management integration is running in the field yet. - Clinical oversight: Clinician-authored pathways and rules; advisory output; escalation policies configurable per institution. ──────────────────────────────────────────────────────────────────────── SAFE-DISCHARGE TRIAL (from /evidence and /faq) ──────────────────────────────────────────────────────────────────────── - Registration: ACTRN12625001425482 — https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12625001425482 - Internal identifier: AES-SAFE-CTS-001 - Site: Royal Prince Alfred Hospital, Sydney - Unit: Cardiothoracic Surgery Unit - Principal Investigator: Dr Kei Woldendorp, The Baird Institute - Sponsor: Sydney Local Health District (SLHD) - Population: Adult patients post cardiothoracic surgery (CABG, valve, thoracic procedures) - Sample size: 550 patients (50 interim + 500 main), single centre - Design: Prospective, historically controlled, structured post-discharge monitoring across the 30-day post-discharge window - Interim analysis: Pre-specified at 50 patients enrolled - Secondary endpoint: Alert burden — fewer than 1 nurse-actionable flag per patient per week over the 30-day window - Status: Recruiting. Enrolment commenced 21 June 2026 at Royal Prince Alfred Hospital, with the first participant enrolled 24 June 2026. ──────────────────────────────────────────────────────────────────────── DATED COMPANY UPDATES (from /updates, newest first) ──────────────────────────────────────────────────────────────────────── 2026-06-21 — SAFE-Discharge begins recruiting at Royal Prince Alfred Hospital. Aescia's SAFE-Discharge trial began enrolment at the Royal Prince Alfred Hospital cardiothoracic surgical unit on 21 June 2026 and is now recruiting. Prospective single-centre evaluation of Aescia for Hospitals in adults recovering from cardiothoracic surgery, registered with the Australian New Zealand Clinical Trials Registry (ACTRN12625001425482). 2026-04-24 — Aescia enrols in MTAA MedTech Compass. Aescia has joined the Medical Technology Association of Australia's MedTech Compass program, which supports Australian medtech companies moving from concept to commercial adoption across regulatory, reimbursement, and clinical evidence. 2026-04-24 — Team, partners, and a progress log on the site. Published the operating team, added trial-site and research-institute affiliations, unified the contact flow, and started this updates log. 2026-04-24 — SAFE-Discharge ethics approval. The SAFE-Discharge trial at Royal Prince Alfred Hospital has cleared human research ethics review. Site-specific governance and IT assessments follow. 2026-04-15 — CHEO Research Institute PMF programme kickoff. Aescia joined the Product-Market-Fit programme at the CHEO Research Institute in Ottawa, with a paediatric-respiratory post-discharge pathway as the working focus. Four candidate specialties under evaluation: paediatric respiratory, paediatric cardiothoracic adjacency, paediatric gastroenterology, paediatric oncology. 2026-04-14 — Bowel-preparation evidence base compiled. Compiled a ten-document evidence base covering international guidelines, digital interventions, operational economics, diabetes and anticoagulant management, GLP-1, and special populations for colonoscopy preparation. 2026-04-13 — Aescia for Clinics MVP feature-complete. End-to-end walkthrough across patient, clinician, and admin flows. 2026-04-10 — NSW MVP Ventures Round 3 submitted. Application MVPV25RD3347 lodged with Investment NSW. Decision expected late June 2026. 2025-10-20 — Concordia News features Aescia in Beat the Odds program. Aescia participated in Concordia University's Beat the Odds hiring event through the District 3 Innovation Hub. Aescia hired its first Beat the Odds intern through the initiative. Source: https://www.concordia.ca/news/stories/2025/10/20/beat-the-odds-connects-concordia-students-with-district-3-startups.html 2025-09 — Aescia joins District 3 at Concordia University. Aescia joined District 3, Concordia's innovation hub for bio, health, and high-tech startups. ──────────────────────────────────────────────────────────────────────── PARTNER AND PROGRAMME AFFILIATIONS ──────────────────────────────────────────────────────────────────────── - Royal Prince Alfred Hospital — Trial site, SAFE-Discharge — https://www.slhd.nsw.gov.au/rpa/ - The Baird Institute — Cardiothoracic research — https://www.bairdinstitute.org.au - Institute of Academic Surgery — Academic surgery, RPAH — https://www.slhd.nsw.gov.au/rpa/ias/ - CHEO Research Institute — Paediatric Product-Market-Fit programme, Ottawa — https://www.cheoresearch.ca - District 3 Innovation Hub — Concordia University, Montréal — https://district3.co - MTAA MedTech Compass — Medical Technology Association of Australia — https://medtechcompass.org.au ──────────────────────────────────────────────────────────────────────── TEAM ──────────────────────────────────────────────────────────────────────── Founders: - James Kurrle, Founder and CEO. Critical-care physician with ten years of clinical and hospital leadership experience, trained and practised across rural New South Wales (Wagga Wagga) and Sydney. Authors the clinical pathway engine and leads company strategy. https://www.linkedin.com/in/jameskurrle/ - Vasken Dermardiros, Co-founder and CTO. PhD from Concordia University in building-energy machine learning. Owns hosting, AI inference, EMR integration, and the pathway authoring infrastructure that underpins both products. Operating team: - Josh Casey — compliance and cybersecurity. Fractional contributor: privacy impact assessments, cybersecurity posture, and the SOC 2 readiness path that opens with the first US design-partner contract. - Sara Nejatian — design and user experience. Leads product design for the patient-facing web app and the clinician worklist. - Shannon Kurrle — Resident Director of Aescia Pty Ltd (statutory requirement under the Australian Corporations Act; not an operational position). Clinical: - Dr Kei Woldendorp, BMed MBBS MPhil. Cardiothoracic researcher, The Baird Institute and Royal Prince Alfred Hospital. Principal Investigator of the SAFE-Discharge trial and Clinical Advisor to Aescia for Hospitals. Advisory: - A clinical advisory board is being formalised alongside the SAFE-Discharge trial at RPAH and the Product-Market-Fit programme at the CHEO Research Institute. Members are named on the site as each formally joins and consents to public acknowledgement. ──────────────────────────────────────────────────────────────────────── FREE CLINICAL TOOLS ──────────────────────────────────────────────────────────────────────── Colonoscopy surveillance interval calculator — https://www.aesciahealth.com/colonoscopy-surveillance A free, no-login reference tool for health professionals. Enter the bowel-prep quality (Boston Bowel Prep Scale), polyp number, largest polyp size, and histology, and it returns the guideline-recommended post-polypectomy colonoscopy surveillance interval — i.e. when to repeat the colonoscopy — with the exact guideline rule and a verbatim source citation for every result. It is an educational reference that reproduces published guidelines; it is not a medical device and not medical advice, it does not make clinical decisions, and it stores no patient data (the calculation runs in the browser). Guidelines covered, side by side: - United States: US Multi-Society Task Force (USMSTF) 2020. - Canada: no maintained national guideline; the tool offers Ontario (ColonCancerCheck), Alberta (ACRCSP), and British Columbia (BCGuidelines 2022) separately, because they give materially different intervals. - Australia: NHMRC / Cancer Council Australia. - Europe: European Society of Gastrointestinal Endoscopy (ESGE) 2020. Representative intervals (see the tool for the full logic and the exact per- guideline result): a normal colonoscopy is repeated in ~10 years; 1–2 small (<10 mm) tubular adenomas in 7–10 years under USMSTF; an adenoma ≥10 mm, villous histology, or high-grade dysplasia at 3 years; sessile serrated lesions ≥10 mm, with dysplasia, or traditional serrated adenomas at 3 years; piecemeal resection of a lesion ≥20 mm gets a 6-month site check; inadequate bowel prep is repeated within ~1 year. The guidelines diverge — for example, Europe (ESGE) returns 1–4 small adenomas to routine screening whereas the US surveils them, and the three Canadian provinces differ from one another (3–4 small adenomas: Ontario 3 years, Alberta 5 years, British Columbia 10 years). Built by Aescia as a free reference for the endoscopy community. ──────────────────────────────────────────────────────────────────────── CONTACT ──────────────────────────────────────────────────────────────────────── Email: contact@aesciahealth.com For procurement (security pack under NDA): https://www.aesciahealth.com/contact?intent=security-pack